1
|
Sundarkumar V, Wang W, Nagy Z, Reklaitis G. Manufacturing pharmaceutical mini-tablets for pediatric patients using drop-on-demand printing. Int J Pharm 2023; 644:123355. [PMID: 37647980 PMCID: PMC10808949 DOI: 10.1016/j.ijpharm.2023.123355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 08/22/2023] [Accepted: 08/26/2023] [Indexed: 09/01/2023]
Abstract
The pharmaceutical industry has traditionally manufactured medicines in a limited range of dose strengths, with an emphasis on addressing the needs of the largest patient subgroups. This has disadvantaged smaller patient subsets, such as children, who often cannot find drug products in dosage levels suitable for their requirements. In recent years, development of pharmaceutical mini-tablets has emerged as an attractive solution to this problem. These are small-size dosages that offer attractive features such as flexible and personalized drug dosing, ease of swallowing, and tailored drug release, making them an excellent choice for administering medicines to children. This study presents a novel technique for manufacturing pharmaceutical mini-tablets, using a drop-on-demand (DoD) printing system. In this method, a DoD system is used to generate precise droplets of a melt-based formulation, which are then captured and solidified in an inert solvent bath to produce individual mini-tablets. The study also evaluates the performance of this technique for various formulations, and quantifies two critical quality attributes (CQAs) of the resulting mini-tablets: content uniformity and dissolution behavior. The findings demonstrate that the manufactured mini-tablets can meet regulatory specifications for both CQAs, and that their release profiles can be customized by modifying the excipients used. The study also discusses promising areas of application and limitations of this technique.
Collapse
Affiliation(s)
- Varun Sundarkumar
- Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN 47907, USA.
| | - Wanning Wang
- Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN 47907, USA
| | - Zoltan Nagy
- Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN 47907, USA
| | - Gintaras Reklaitis
- Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN 47907, USA
| |
Collapse
|
2
|
Içten E, Maloney AJ, Beaver MG, Zhu X, Shen DE, Robinson JA, Parsons AT, Allian A, Huggins S, Hart R, Rolandi P, Walker SD, Braatz RD. A Virtual Plant for Integrated Continuous Manufacturing of a Carfilzomib Drug Substance Intermediate, Part 2: Enone Synthesis via a Barbier-Type Grignard Process. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00188] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Elçin Içten
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Andrew J. Maloney
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Matthew G. Beaver
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Xiaoxiang Zhu
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Dongying E. Shen
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Jo Anna Robinson
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Andrew T. Parsons
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Ayman Allian
- Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Seth Huggins
- Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Roger Hart
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Pablo Rolandi
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Shawn D. Walker
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Richard D. Braatz
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
3
|
Içten E, Maloney AJ, Beaver MG, Shen DE, Zhu X, Graham LR, Robinson JA, Huggins S, Allian A, Hart R, Walker SD, Rolandi P, Braatz RD. A Virtual Plant for Integrated Continuous Manufacturing of a Carfilzomib Drug Substance Intermediate, Part 1: CDI-Promoted Amide Bond Formation. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00187] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Elçin Içten
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Andrew J. Maloney
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Matthew G. Beaver
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Dongying Erin Shen
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Xiaoxiang Zhu
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Lauren R. Graham
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Jo Anna Robinson
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Seth Huggins
- Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Ayman Allian
- Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Roger Hart
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Shawn D. Walker
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Pablo Rolandi
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Richard D. Braatz
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
4
|
Radcliffe AJ, Hilden JL, Nagy ZK, Reklaitis GV. Dropwise Additive Manufacturing of Pharmaceutical Products Using Particle Suspensions. J Pharm Sci 2018; 108:914-928. [PMID: 30308177 DOI: 10.1016/j.xphs.2018.09.030] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 09/05/2018] [Accepted: 09/14/2018] [Indexed: 11/16/2022]
Abstract
The principal method of drug delivery is by oral solid doses, the production of which often necessitates multiple post-crystallization unit operations to ensure content uniformity or enhance bioavailability. As an alternative to conventional dose production methods, applications of additive manufacturing technologies based on solvent- or melt-based formulations have demonstrated the potential for improvements to process efficiency, flexibility, and dosing precision. Here we explore the use of particulate suspensions in a dropwise additive manufacturing process as a method for dosing active ingredients in crystalline form, which may be difficult to achieve via powder processing due to poor flow properties. By employing a fluid-based method, powder flow issues are alleviated and adaptation of the process to new particles/crystals is facilitated by dimensional analysis. In this work, a feasibility study was conducted using 4 active ingredient powders, each with non-ideal particle properties, and 2 carrier fluids, in which the active ingredient does not dissolve, to formulate suspensions for dose manufacturing; drug products were analyzed to show reproducibility of dosing and to assess preservation of particle size through the process. Performance across particle types is affected by particle size and shape, and is related through effects on the rheological properties of the formulation.
Collapse
Affiliation(s)
- Andrew J Radcliffe
- Department of Chemical Engineering, Purdue University, West Lafayette, Indiana.
| | - Jon L Hilden
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana
| | - Zoltan K Nagy
- Department of Chemical Engineering, Purdue University, West Lafayette, Indiana
| | | |
Collapse
|
5
|
QR encoded smart oral dosage forms by inkjet printing. Int J Pharm 2018; 536:138-145. [DOI: 10.1016/j.ijpharm.2017.11.052] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 11/21/2017] [Accepted: 11/22/2017] [Indexed: 12/23/2022]
|
6
|
Içten E, Purohit HS, Wallace C, Giridhar A, Taylor LS, Nagy ZK, Reklaitis GV. Dropwise additive manufacturing of pharmaceutical products for amorphous and self emulsifying drug delivery systems. Int J Pharm 2017; 524:424-432. [DOI: 10.1016/j.ijpharm.2017.04.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2016] [Revised: 03/26/2017] [Accepted: 04/02/2017] [Indexed: 12/30/2022]
|
7
|
Içten E, Joglekar G, Wallace C, Loehr K, Sacksteder J, Giridhar A, Nagy ZK, Reklaitis GV. Knowledge Provenance Management System for a Dropwise Additive Manufacturing System for Pharmaceutical Products. Ind Eng Chem Res 2016. [DOI: 10.1021/acs.iecr.6b01042] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Elçin Içten
- School
of Chemical Engineering, Purdue University, West Lafayette, Indiana 47907-2100, United States
| | - Girish Joglekar
- School
of Chemical Engineering, Purdue University, West Lafayette, Indiana 47907-2100, United States
| | - Chelsey Wallace
- School
of Chemical Engineering, Purdue University, West Lafayette, Indiana 47907-2100, United States
| | - Kristen Loehr
- School
of Chemical Engineering, Purdue University, West Lafayette, Indiana 47907-2100, United States
| | - Jennifer Sacksteder
- School
of Chemical Engineering, Purdue University, West Lafayette, Indiana 47907-2100, United States
| | - Arun Giridhar
- School
of Chemical Engineering, Purdue University, West Lafayette, Indiana 47907-2100, United States
| | - Zoltan K. Nagy
- School
of Chemical Engineering, Purdue University, West Lafayette, Indiana 47907-2100, United States
| | - Gintaras V. Reklaitis
- School
of Chemical Engineering, Purdue University, West Lafayette, Indiana 47907-2100, United States
| |
Collapse
|
8
|
Process control of a dropwise additive manufacturing system for pharmaceuticals using polynomial chaos expansion based surrogate model. Comput Chem Eng 2015. [DOI: 10.1016/j.compchemeng.2015.07.014] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|